Evidence map›Paper›PMID 37399214›Full record

ArticlePLoS neglected tropical diseases2023

Smartphone-readable RPA-LFA for the high-sensitivity detection of Leishmania kDNA using nanophosphor reporters.

Adheesha N Danthanarayana, Suman Nandy, Katerina Kourentzi, Binh Vu, Thomas R Shelite, Bruno L Travi, Jakoah Brgoch, Richard C Willson

Abstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Development of Time-Resolved Luminescence Measurement Instruments for Biosensing and Bioimaging - An Overview.Measurement : journal of the International Measurement Confederation · 2025
    Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Adheesha N DanthanarayanaDepartment of Chemistry, University of Houston, Houston, Texas, United States of America.ORCID 0000-0003-1632-1418
Suman NandyWilliam A. Brookshire Department of Chemical and Biomolecular Engineering, University of Houston, Houston, Texas, United States of America.
Katerina KourentziWilliam A. Brookshire Department of Chemical and Biomolecular Engineering, University of Houston, Houston, Texas, United States of America.
Binh VuWilliam A. Brookshire Department of Chemical and Biomolecular Engineering, University of Houston, Houston, Texas, United States of America.
Thomas R SheliteDepartment of Biosafety, University of Texas Medical Branch, Galveston, Texas, United States of America.
Bruno L TraviDepartment of Internal Medicine, University of Texas Medical Branch, Galveston, Texas, United States of America.
Jakoah BrgochDepartment of Chemistry, University of Houston, Houston, Texas, United States of America.
Richard C WillsonWilliam A. Brookshire Department of Chemical and Biomolecular Engineering, University of Houston, Houston, Texas, United States of America.ORCID 0000-0002-0900-6148

Funding

Rapid Fluorescence-Based Determination of Antibiotic SusceptibilityU54EB015408 · NIBIB · MASSACHUSETTS GENERAL HOSPITAL · PI PARRISH, JOHN A, SCHACHTER, STEVEN · 2012 to 2022
$49.2M
Novel Point of Care assays for Urinary Diagnostics of NephritisR01AR072742 · NIAMS · UNIVERSITY OF HOUSTON · PI MOHAN, CHANDRA, WILLSON, RICHARD · 2017 to 2020
$1.3M
Smartphone-based POC Testing for HIV Using Glowstick ChemistryR61AI174294 · NIAID · UNIVERSITY OF HOUSTON · PI WILLSON, RICHARD · 2023 to 2025
$1.3M
A smartphone-based point-of-care test for detection of Chlamydia trachomatisR43AI118180 · NIAID · LUMINOSTICS, INC. · PI PATERSON, ANDREW SLATOR, WILLSON, RICHARD · 2016 to 2016
$219k
ACL HHS U01CK000512NCEZID CDC HHS U01 CK000512NIAID NIH HHS R43 AI118180NIAID NIH HHS R61 AI174294NIAMS NIH HHS R01 AR072742NIBIB NIH HHS U54 EB015408
6 · The paper itself

Abstract

Early diagnosis of infectious diseases improves outcomes by enabling earlier delivery of effective treatment, and helps prevent further transmission by undiagnosed persons. We demonstrated a proof-of-concept assay combining isothermal amplification and lateral flow assay (LFA) for early diagnosis of cutaneous leishmaniasis, a vector-borne infectious disease that affects ca. 700,000 to 1.2 million people annually. Conventional molecular diagnostic techniques based on polymerase chain reaction (PCR) require complex apparatus for temperature cycling. Recombinase polymerase amplification (RPA) is an isothermal DNA amplification method that has shown promise for use in low-resource settings. Combined with lateral flow assay as the readout, RPA-LFA can be used as a point-of-care diagnostic tool with high sensitivity and specificity, but reagent costs can be problematic. In this work, we developed a highly-sensitive smartphone-based RPA-LFA for the detection of Leishmania panamensis DNA using blue-emitting [(Sr0.625Ba0.375)1.96Eu0.01Dy0.03]MgSi2O7 (SBMSO) persistent luminescent nanophosphors as LFA reporters. The greater detectability of nanophosphors allows the use of a reduced volume of RPA reagents, potentially reducing the cost of RPA-LFA. The limit of detection (LOD) of RPA with gold nanoparticle-based LFA readout is estimated at 1 parasite per reaction, but LOD can be 100-fold better, 0.01 parasites per reaction, for LFA based on SBMSO. This approach may be useful for sensitive and cost-effective point-of-care diagnosis and contribute to improved clinical and economic outcomes, especially in resource-limited settings.

Indexed as

LeishmaniaMetal NanoparticlesDNA, KinetoplastGoldHumansNucleic Acid Amplification TechniquesRecombinasesSensitivity and SpecificitySmartphoneDNA, KinetoplastGoldRecombinases

Identifiers

PMID37399214
PMCPMC10353800

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.